Last update :
16/01/2021
Anticancer drug   Cisplatin  
Injection
Stability in solutions Stability of mixtures Factors which affect stability Incompatibilities Route of administration References Pdf
   Chemical structure  

Tradename   Tradename     

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Abiplatin Republic of South Africa
Accocit Mexico
Briplatin Japan
Cisplatex Brazil
Cisplatine France
Cisplatyl France, Greece, Turkey
Citoplatino Italy
Neoplatin Spain
Pamifect India
Placis Spain, Turkey
Platamine Greece, Italy, Morocco, Tunisia
Platidiam Hungary, Poland
Platinex Germany, Great Britain, Italy
Platinol Austria, Belgium, Denmark, Finland, Greece, Luxembourg, Mexico, Netherlands, Sweden, Switzerland, United States of America
Platistil Spain
Platistine Belgium, Brazil, Luxembourg
Platosin Belgium, Egypt, Greece, Japan, Netherlands, Romania, Turkey, Venezuela
Pronto Platamine Italy
Tecnoplatine Mexico
References   Injection   References : Cisplatin  
Type Publication
3 Journal Trissel LA, Martinez JF.
Compatibility of amifostine with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
53 Journal Henry DW, Marshall JL, Nazzar OD, Fox JL, Leff RD.
Stability of cisplatin and ondansetron hydrochloride in admixtures for continuous infusion.
Am J Health-Syst Pharm 1995 ; 52: 2570-2573.
57 Journal Mayron D, Gennaro AR.
Stability and compatibility of granisetron hydrochloride in IV solutions and oral liquids and during simulated Y-site injection with selected drugs.
Am J Health-Syst Pharm 1996 ; 53: 294-304.
81 Journal Trissel LA, Martinez JF.
Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 672-678.
91 Journal Lober CA, Dollard PA.
Visual compatibility of gallium nitrate with selected drugs during Y-site injection.
Am J Hosp Pharm 1993 ; 50: 1208-1210.
147 Journal Pujol Cubells M, Prat Aixela J, Girona Brumos V, Duran Pou S, Villaronga Flaque MV.
Stability of cisplatin in sodium chloride 0.9% intravenous solution related to the container’s material.
Pharm World Sci 1993 ; 15: 34-36.
149 Journal Rochard E, Barthes D, Courtois P.
Stability of cisplatin in ethylene vinylacetate portable infusion-pump reservoirs.
J Clin Pharm Ther 1992 ; 17: 315-318.
164 Journal Benaji B, Dine T, Luyckx M, Brunet C, Goudaliez F, Mallevais ML, Cazin M, Gressier B, Cazin JC.
Stability and compatibility of cisplatin and carboplatin with PVC infusion bags.
J Clin Pharm Ther 1994 ; 19: 95-100.
249 Journal Trissel LA, Martinez JF.
Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
301 Journal Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM.
Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
409 Journal Cheung YW, Cradock JC, Vishnuvajjala BR, Flora KP.
Stability of cisplatin, iproplatin, carboplatin, and tetraplatin in commonly used intravenous solutions.
Am J Hosp Pharm 1987 ; 44: 124-130.
410 Journal Zieske PA, Koberda M, Hines JL, Knight CC, Sriram R, Raghavan NV, Rabinow BE.
Characterization of cisplatin degradation as affected by pH and light.
Am J Hosp Pharm 1991 ; 48: 1500-1506.
413 Journal Stewart CF, Fleming RA.
Compatibility of cisplatin and fluorouracil in 0.9% sodium chloride injection.
Am J Hosp Pharm 1990 ; 47: 1373-1377.
417 Journal Stewart CF, Hampton EM.
Stability of cisplatin and etoposide in intravenous admixtures.
Am J Hosp Pharm 1989 ; 46: 1400-1404.
660 Journal Michaels MR, Stauffer GL, Haas DP.
Propofol compatibility with other intravenous drug products - Two new methods of evaluating IV emulsion compatibility.
Ann Pharmacotherapy 1996 ; 30: 228-232.
742 Journal Greene RF, Chatterji DC, Hiranaka PK, Gallelli JF.
Stability of cisplatin in aqueous solution.
Am J Hosp Pharm 1979 ; 36: 38-43.
855 Journal Hrubisko M, Mc Gown AT, Prendiville JA, Radford JA, Thatcher N, Fox BW.
Suitability of cisplatin solutions for 14-day continuous infusion by ambulatory pump.
Cancer Chemother Pharmacol 1992 ; 29: 252-255.
921 Journal Trissel LA, Gilbert DL, Martinez JF.
Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration.
Hosp Pharm 1998 ; 33: 284-292.
1026 Journal Mayron D, Gennaro AR.
Stability and compatibility of topotecan hydrochloride with selected drugs.
Am J Health-Syst Pharm 1999 ; 56: 875-881.
1080 Journal La Folette JM, Arbus MH, Lauper RD.
Stability of cisplatin admixtures in polyvinyl chloride bags.
Am J Hosp Pharm 1985 ; 42: 2652.
1625 Journal Trissel LA, Saenz C, Williams YW, Ingram D.
Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration.
Int J Pharm Compound 2001 ; 5: 314-321.
1729 Journal Mittner A, Vincze Z, Jemnitz K.
Stability of cisplatin containing infusion.
Pharmazie 1998 ; 53: 490-492.
1950 Journal Trissel LA, Yanping Z.
Physical and chemical stability of palonosetron HCl with cisplatin, carboplatin and oxaliplatin during simulated Y-site administration.
J Oncol Pharm Practice 2004 ; 10: 191-195.
3183 Journal Sewell G
Physical and chemical stability of cisplatin infusions in PVC containers.
EJOP 2010 ; 4, 3: 11-13.
3474 Manufacturer Fluorouracil - Summary of Product Characteristics
Accord Healthcare Limited 2009
3578 Manufacturer Cisplatin - Summary of Product Characteristics
Accord Healthcare 2011
3602 Manufacturer Mesna (Uromitexan®)- Summary of Product Characteristics
Baxter SAS 2013
3670 Journal Sewell G, Massimini M.
Studies on the stability and compatibility of cytotoxic drug infusion with the Tevadaptor system.
EJOP 2014 ; 8, 3: 26-30.
4084 Manufacturer Cisplatine - Résumé des caractéristiques du produits
Accord Health Care 2017
4137 Journal Patel T, Sewell G.
Short Report : Extended Stability Studies on Bortezomib Injection and Infusions of Cisplatin and Pemetrexed (all Accord Healthcare).
Newsletter Stabilis 2018 41;2-6

  Mentions Légales